Revance Therapeutics Inc (NAS:RVNC)
$ 3.04 -0.02 (-0.65%) Market Cap: 317.35 Mil Enterprise Value: 618.80 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Q3 2020 Revance Therapeutics Inc Earnings Call Transcript

Nov 09, 2020 / 09:30PM GMT
Release Date Price: $27.6 (+3.99%)
Operator

Welcome to the Revance Therapeutics Third Quarter 2020 Financial Results and Corporate Update Conference Call. (Operator Instructions)

As a reminder, this call is being recorded today, November 9, 2020. I would now like to turn the conference over to Jeanie Herbert, Head of Investor Relations for Revance. Please go ahead.

Jeanie D. Herbert
Revance Therapeutics, Inc. - Senior Director of IR & Corporate Communications

Thank you, Daphne. Joining us on the call today from Revance are President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi; Chief Commercial Officer, Therapeutics and Aesthetics, Dustin Sjuts; President of Innovation and Technology, Aubrey Rankin; and Senior Vice President, Clinical Development, Dr. Roman Rubio.

Earlier today, Revance released financial results for the third quarter ended September 30, 2020, and top line results from the Phase II trial of DaxibotulinumtoxinA for Injection in plantar

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot